Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on RGLS stock, giving a Buy rating on March 28.
Joseph Schwartz has given his Buy rating due to a combination of factors that highlight the potential of Regulus’s treatment, farabursen, in addressing autosomal dominant polycystic kidney disease (ADPKD). The recent data from the fourth cohort of the Phase 1b study demonstrated promising results, showing that farabursen can effectively halt the growth of height-adjusted total kidney volume (htTKV) in patients, which is a critical measure in managing ADPKD.
Moreover, the safety profile of farabursen was favorable, aligning with previous cohorts, and the company is preparing for a pivotal study that could lead to Accelerated Approval. The consistency of the data across different cohorts enhances confidence in the program’s potential success. Additionally, the comparison with historical placebo groups further underscores the efficacy of farabursen, making Regulus a compelling investment opportunity.
In another report released on March 28, Oppenheimer also maintained a Buy rating on the stock with a $7.00 price target.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RGLS in relation to earlier this year.